Loading clinical trials...
Loading clinical trials...
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Moderate to Severe Interdigital Tinea Pedis
Conditions
Interventions
VT-1161
placebo
Locations
7
United States
Univ Alabama at Birmingham
Birmingham, Alabama, United States
Florida Academic Dermatology Center
Miami, Florida, United States
FXM Research
Miramar, Florida, United States
Wake Research Associates
Raleigh, North Carolina, United States
Oregon Dermatology & Research Center
Portland, Oregon, United States
J&S Studies, Inc.
College Station, Texas, United States
Start Date
August 1, 2013
Primary Completion Date
December 1, 2014
Completion Date
December 1, 2014
Last Updated
August 1, 2018
NCT07245667
NCT00233493
NCT03129321
NCT03897257
NCT03135912
NCT02606383
Lead Sponsor
Viamet
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions